Achilles Therapeutics plc reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 61.1 million compared to USD 33.2 million a year ago. Basic loss per share from continuing operations was USD 2.13 compared to USD 31.14 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.26 USD | +5.88% | -2.36% | +39.48% |
Dec. 14 | BofA Securities Downgrades Achilles Therapeutics to Underperform From Buy, Price Target is $0.50 | MT |
Nov. 14 | Syncona notes investee company's quarterly loss | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.48% | 48.53M | |
+9.16% | 45.97B | |
+52.73% | 43.93B | |
+7.55% | 42.34B | |
-8.78% | 28.27B | |
+18.59% | 27.18B | |
-21.12% | 19.44B | |
+14.45% | 13.83B | |
+31.55% | 12.4B | |
+7.64% | 11.45B |
- Stock
- Equities
- Stock Achilles Therapeutics plc - Nasdaq
- News Achilles Therapeutics plc
- Achilles Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2021